Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Income from Continuing Operations (2016 - 2025)

Cumberland Pharmaceuticals' Income from Continuing Operations history spans 16 years, with the latest figure at 1415166.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 25.69% year-over-year to 1415166.0; the TTM value through Dec 2025 reached 2851235.0, up 55.69%, while the annual FY2025 figure was 2851235.0, 55.77% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 1415166.0 at Cumberland Pharmaceuticals, up from 1949046.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1248184.0 in Q1 2025 and bottomed at 4387576.0 in Q4 2021.
  • The 5-year median for Income from Continuing Operations is 1364666.0 (2022), against an average of 1082216.58.
  • The largest annual shift saw Income from Continuing Operations tumbled 1204.25% in 2024 before it skyrocketed 165.61% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 4387576.0 in 2021, then skyrocketed by 43.94% to 2459714.0 in 2022, then soared by 56.77% to 1063219.0 in 2023, then crashed by 79.11% to 1904306.0 in 2024, then rose by 25.69% to 1415166.0 in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Income from Continuing Operations are 1415166.0 (Q4 2025), 1949046.0 (Q3 2025), and 735207.0 (Q2 2025).